OHSU research shows vitamin C counteracts some negative impacts of smoking on unborn babies
Research conducted in monkeys at the Oregon National Primate Research Center, Oregon Health & Science University, suggests high doses of vitamin C may have potential to counteract some negative impacts of smoking in unborn babies. The research may benefit thousands of babies born to mothers who continue to smoke throughout pregnancy despite physician warnings. The research is published in the...Health of Acehnese reefs in the wake of the tsunami shows human impacts more harmful
According to research reported this week in Current Biology, tsunami damage to coral reefs closest to the epicenter of the 2004 Sumatra-Andaman earthquake was occasionally spectacular, but surprisingly limited, particularly when compared to damage from chronic human misuse in the region. Less than 100 days after the tsunami of December 26, 2004, a team of ecologists from James Cook Univer...Superconducting magnet attracts molecular research
One of the newest - and unequivocally the coolest - pieces of real estate on the Brandeis University campus is a facility containing a state-of-the-art superconducting magnet for use in researching biological macromolecules such as DNA, RNA, enzymes and other proteins. The installation of the gleaming 800 MHz German-made Bruker magnet was recently completed in a specially built facility o...Anthrax inhibitor counteracts toxin, may lead to new therapeutics
Researchers from Rensselaer Polytechnic Institute and the University of Toronto have designed a nanoscale assembly of molecules that successfully counteracts and inhibits anthrax toxin in animal and laboratory experiments. The novel approach used to neutralize anthrax toxin could be applied in designing potent therapeutics for a variety of pathogens and toxins, according to the researchers. <...New 'implanted contacts' designed to fix nearsightedness
UT Southwestern Medical Center ophthalmologists will be the first in the area to insert a new type of implanted lens to fix nearsightedness. , who is inserting the new implantable collamer lens, or ICL, today for the first time at UT So...The Protein Kinase Factsbooks (2 Volume Set) from Promega
Description:The Protein Kinase Factsbooks (2 Volume Set)...SLE of Eau Claire lands $2.2 million in federal contracts
In a long-planned departure from its traditional focus, high-end computer chip company Silicon Logic Engineering has contracted with the U.S. Army for development of two different products. SLE, based in Eau Claire, announced today that it has secured $2.2 million in federal contracts for fiscal year 2005. The company has been working with the Armys Research, Development and Engineering...Quantitative Analysis of GFP in Plant Extracts Using the VersaFluor Fluorometer System
CSIRO Tropical Agriculture, Brisbane, Queensland The Green Fluorescent Protein (GFP) from Aequorea victoria is a useful reporter gene in higher organisms, including plants and animals. The fluorescence emitted is easy to det...Research consortium aims to bring security and defense contracts to Wisconsin
The , has stake...Shades of gray: Business impacts of an aging workforce
Many of these press accounts would lead one to believe that...Doyle signs bill that impacts electronic medical records
Senate Bill 650 creates an exception to current law pertaining to the confidentiality of treatment records, allowing physicians easier access to mental health records wh...Advances in Treatment of Cataracts
Cataracts occur when the eye's lens becomes cloudy and obstructs the passage of light to the retina. These obstructions can lead to vision loss. //Cataract is a major cause of blindness in India. Modern corrective surgery requires implantation of artificial lenses, however these implants often leave patients dependent on eyeglasses. But now, a recent study at Harvard Medical School has sh...WHO acts to reduce the maternal death toll
According to a WHO report more than half a million women in developing countries dies of childbirth each year. WHO and the Partnership for Safe Motherhood and Newborn Health //are intensifying support to countries around the world to ensure that a woman does not die while giving birth to her child. The report indicates that the needs are wide-ranging - from training skilled birth atte...Sleep disorders can have anomalistic sexual acts
Researchers at the University of California, observe abnormal behavior during sleep, such as walking, eating and even violence in many people. But a series of case reports shows that sleep disorders// can also involve unconscious, sometimes aggressive, sexual behavior. In a study of 10 patients with "atypical sexual behavior during sleep," researchers found that the patients' actions w...Prechopper straight for soft cataracts
Description:Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....Prechopper angled for soft cataracts
Description:Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....Prechopper curved for soft cataracts
Description:Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....Ascensia Win Glucofacts Diabetes Management Software
Description:Use the Ascensia WinGlucofacts software to download results from the Ascensia BREEZE, Ascensia DEX 2, or the Ascensia ELITE XL blood glucose monitoring system. The software helps users manage their diabetes through automatic calculation of averages and historical data....OXiGENE Abstracts Published in ASCO Program
WALTHAM, Mass.--(BUSINESS WIRE)--Jun 1, 2007 - OXiGENE, Inc.(NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biopharmaceuticalcompany developing novel therapeutics to treat cancer and eyediseases, announced today the publication of two abstracts in the2007 Annual Meeting program distributed this afternoon at theAnnual Meeting of the American Society of Clinical Oncology (ASCO)in Chicago, IL.<p...Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
- Phase I data from XL880, Phase II data from XL999 studiesscheduled for presentation during oral, poster sessions - SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ --Exelixis, Inc. announced today that data from clinical trials ofthe company's investigational compounds XL880 and XL999 will bepresented at the 2007 American Society of Clinical Oncology AnnualMeeting (ASCO), which...